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Wilson's disease is a rare autosomal recessive disorder of copper metabolism that often proves a 
difficult diagnosis for the both the clinician and pathologist largely because of its low incidence and 
variable presentations.  There have been few studies detailing the histopathological features of hepatic 
specimens in patients with Wilson's disease and fewer correlating these features with clinical 
presentation.  When left untreated, the disease is ultimately fatal, thus good diagnostic criteria that take 
into account the histopathological features of the disease is important.  The aim of this study was to 
evaluate the histopathological features of hepatectomy and biopsy specimens in patients with Wilson's 
disease and correlate these features with the clinical parameters of these patients.   Twelve biopsy and 
hepatectomy specimens from patients with Wilson's disease were reviewed and placed into three 
categories: (A) Near normal/mild, (B) Chronic hepatitis and (C) Acute injury on chronic 
hepatitis/decompensated cirrhosis.  The clinical presentations were reviewed and any correlation 
between clinical parameters and anatomic features reported.  Histopathological features consistent with 
previous findings in the early stages of Wilson's disease were found in group A with clinical findings in 
this category of mild elevation of transaminases.  In group B, while typical markers of chronic hepatitis 
were found, glycogenated nuclei, a feature often reported as prominent in specimens with Wilson’s 
disease hepatitis was absent.  There was one patient with relevant laboratory data in this group, which 
was notable for mild elevations of transaminases.  In group C, features of acute on chronic injury were 
found.  Regarding clinical parameters, transaminases and bilirubin levels were increased, and alkaline 
phosphatase:total bilirubin ratio was consistent with previously reported findings of fulminant hepatic 
failure in Wilson’s disease.   Urinary copper levels increased with increasing levels of histopathological 
injury.  Staining for copper proved to be an unreliable method of diagnosis.  This characterization of 
the histopathological and clinical features of Wilson’s disease further elucidates the challenge of 
Wilson’s disease but also serves to provide some guidance to both clinician and pathologist as to how 
recognizing the variable presentations of the disease may help in establishing a diagnosis. 
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Wilson's disease is an autosomal recessive disorder of copper metabolism named for Samuel 
Kinnier Wilson. He initially described it as progressive lenticular degeneration because of case 
observations of patients with lenticular nucleus degeneration and cirrhosis of the liver1.  The disease 
has a prevalence of 1 in 30,000 worldwide. In some areas, prevalences as high as 1 in 2,600 have been 
reported. These areas are typically those of high consanguinity2.   
 
The etiology of Wilson’s disease involves greater than 300 mutations3 in the gene encoding a P 
type ATPase ATPB7, which is involved in both the incorporation of copper into apoceruloplasmin, a 
copper carrying protein in the hepatocyte, and into bile for excretion.   Malfunction or absence of 
ATP7B leads to a build up of free (unbound) copper in the brain, cornea and liver.  The clinical 
consequences of this build up are neuropsychiatric (Parkinsonian symptoms, depression, suicidality), 
ophthalmologic (Kaiser-Fleischer rings i.e. copper build up in the irises of affected individuals) and 
hepatic (steatosis, cirrhosis, hepatitis).   
 
With early diagnosis and implementation of treatment (primarily chelation therapy), symptom 
progression and, in some cases, symptom onset can be thwarted.  Even though there are regularly 
updated diagnostic criteria4, Wilson's disease is known for its high phenotypic and genotypic 
heterogeneity, which makes it a diagnostic challenge for clinician and pathologist alike.  In addition, 
though early treatises have described the pathology of Wilson disease in detail5, more recent discourses 
have not been as comprehensive, nor has there been significant correlation between clinical and 
pathologic features. The aim of this project was to describe the spectrum of pathological changes of 
Wilson's disease in our patients with emphasis on correlation with clinical features and diagnostic 






Wilson's disease mutations and Molecular Pathology 
 
The genetics, molecular pathology and pathophysiology of the disease have been described 
extensively6.   In summary, mutations of the Wilson disease gene result in abnormal metabolism of 
copper.   Dietary copper is primarily metabolized by the liver and circulates through the body as 
ceruloplasmin with help from P type ATPases ATP7A and ATP7B.  While both ATP7A and ATP7B 
are copper transporting proteins, they serve different physiological functions due to the difference of 
their expression in tissues.  ATP7A is primarily localized in the basement membrane of the enterocyte 
and serves to transport copper into portal circulation.  ATP7B, however, is present in the hepatocyte 
and plays a major role in the incorporation of copper into apoceruloplasmin.  Because of their varying 
roles, mutations in ATP7A and ATP7B inevitably cause different diseases.  Mutations in the ATPase 
ATP7A have been implicated in Menke’s disease, an X-linked neurodegenerative disease in which 
hypocupremia is the main laboratory diagnostic feature.  Mutations in ATP7B (located on chromosome 
13) are responsible for the development of Wilson’s disease.   
 
ATP7B is primarily localized to the trans-Golgi network of the hepatocyte. Copper enters the 
hepatocyte via a copper transporter Ctr1. The copper chaperone ATOX1 then delivers intracellular 
copper to ATP7B.  There, ATP7B facilitates the binding of copper to apoceruloplasmin and the 
subsequent secretion of holoceruloplasmin (copper bound to apoceruloplasmin) into plasma.  Biliary 
excretion of copper also involves ATP7B however, there is direct interaction with another protein, 
COMMD16 (previously known as MURR1).   The exact function of this ubiquitous protein is yet to be 
elucidated.  However, it is absent in dogs with a non-Wilsonian form of copper toxicosis,  Further 




investigation showed that COMMD1 is able to bind to ATP7B and aid in the transport of ATP7B 
bound copper from the trans-Golgi to the bile canaliculus7. 
Ceruloplasmin acts as an oxidase in selected substrate reactions1.  Interestingly, ceruloplasmin 
is the major ferroxidase in the body and also aids in iron efflux.  The associated disorder of iron 
metabolism leads to increased liver iron stores so much so that some Wilson's disease patients with 
hypoceruloplasminemia have been mistakenly diagnosed with hereditary hemochromatosis because of 
apparent iron overload in the liver1. 
 
ATP7B is a large 21 exon gene which codes for a 1465 amino acid transmembrane protein.  The 
carrier frequency of the gene for this protein is 1 in 90 while the gene frequency is 0.56%8.  The most 
common mutation detailed in Wilson's disease is H1069Q, it is found in 37% to 63% of patients with 
Wilson’s disease of European ancestry3.  This mutation leads to a failure of trafficking of the protein to 
its usual position in the trans-Golgi.  Other, more recently discovered mutations include R778L (the 
protein is mislocalized to the endoplasmic reticulum) and P992L found with high frequency in patients 
with Wilson’s disease of Chinese ancestry presenting with primarily hepatic complaints3.    Most 
recently, methylenetetrahydrofolate reductase (MTHFR) mutations found in Wilson’s disease patients 
were implicated as a potential cause for the high phenotypic variability of the disease.  Patients with 
particular polymorphisms were less likely than others to exhibit the neurological Wilson’s disease 
phenotype9.  
 
There have been some studies attempting to detail the genotype-clinical phenotype correlation 
in Wilson's disease10,11.  This proves difficult as there are numerous mutations of ATP7B and each 
mutation is assumed to have significant pleiotropy.  In fact, there may be associated mutations in non-
ATP7B proteins such as COMMD1, which may cause similar symptoms. Mutations also vary 




extensively by population.  In screening recommendations for example, in Northern Chinese 
populations exons 8, 12, 13, 16 and 18 should be screened while exons 5,8, 12, 13 and 16 should be 
screened in Hong Kong9.  All of these factors thus limit the clinical application of molecular studies as 
a primary tool of diagnosis.  Identification of unique pathological features in liver biopsies therefore 
potentially presents a reliable ancillary method of making the diagnosis when fulfillment of diagnostic 




Light microscopy of liver biopsies in patients with Wilson's disease has yielded a variety of 
findings and presents a challenge for the pathologist.  In general, features described have included 
steatosis, glycogenated nuclei and occasional positive staining with rhodanine stains.  Published studies 
on the ultrastructural pathology of Wilson's disease have been limited, partly due to the absence of an 
electron microscope in most institutions as a standard tool for evaluating pathology specimens, and 
partly due to the onset of molecular techniques and the readiness with which copper can be quantified 
in the liver.  Other diagnostic tools explored include diagnosis of  Wilson's disease by skin biopsy12.  In 
a patient presenting with Kayser Fleischer rings and xerosis of the skin, light microscopy of the skin 
showed hyperkeratosis.  Electron microscopy showed dilatation of intercellular space and lysosomes 
with a heterogenous and granular appearance (incidentally all nonspecific findings of xerosis).  
However, spectophotometric measurement determined that copper levels in the skin were significantly 
higher than the control, one of few studies to highlight skin as another potential organ damaged by 
excess copper. 
 
Transmission electron microscopy along with energy dispersive x-ray spectroscopy have shown 




lipofuscin particles containing copper-sulfur (cuprothioneins) and iron phosphorous complexes in the 
hepatocyte lysosomes of one patient with Wilson's disease13. This is considered to be a diagnostic 
ultrastructural feature.  Although other diagnostic features include mitochondrial enlargement and 
widening of intercristal spaces suggested to be pathognomonic of Wilson’s disease, they are unreliable 




In early stages of the disease, the damage incurred by copper accumulation has been associated 
with macrosteatosis, microsteatosis and glycogenated nuclei14.  Mallory bodies can be seen in up to 
50% of biopsy specimens.  There are few reports on Wilson’s disease patients presenting with acute 
hepatitis; their biopsies typically show ballooning of hepatocytes, apoptotic bodies, cholestasis and 
sparse lymphocytic infiltrate14.  In Acute Liver Failure (ALF) histopathology resembling fulminant 
hepatitis is typically observed.  This is characterized by microvesicular steatosis, marked balloon 
degeneration, apoptosis, pigment laden Kupffer cells and parenchymal dropout with lobular collapse.   
 
As the disease progresses to cirrhosis, portal inflammation, focal necrosis and glycogenated 
nuclei are common findings in hepatic specimens.  The literature points to steatosis, glycogenated 
nuclei and the presence of Mallory bodies in periportal liver cells as features used to distinguish the 
chronic hepatitis of Wilson’s disease from other more common etiologies14.  Autoimmune hepatitis is 
often mentioned as appearing similar to Wilson’s disease.  And while lobular necroinflmmatory 
lesions, ballooning degeneration and interface hepatitis are diagnostic features of both, giant cell 
change is predominant in the former. 
 




In some cases, cirrhosis develops.  A mixed micro/macronodular pattern may be observed 
although most reports show a macronodular pattern of cirrhosis.  Features observed in the chronic 
hepatitis of Wilson’s disease are also observed (i.e. inflammation, Mallory bodies within hepatocytes) 




Standard staining is neither sensitive nor specific for the detection of tissue copper.  Initially 
hematoxylin was used for the demonstration of tissue copper.  Further investigation into the diagnosis 
of Wilson's disease via histochemical visualization of tissue copper led to the development of the now 
commonly used rhodanine and rubeanic acid stains.  Other less common stains are: diphenylcarbazide, 
Waterhouse method, cresyl violet stain, dithizone and Timm's method.  The orcein method is the most 
recent development for detecting tissue copper, it was developed in 1974 and stains metallothioneins 
(copper-binding proteins).   
 
Consensus on the distribution and staining of copper within the liver in patients with Wilson’s 
disease has not been achieved and remains controversial since there are varying reports in the literature.  
It has been shown that in the early stages of the disease, copper is distributed throughout the hepatocyte 
cytoplasm14.  As the disease progresses, in addition to cytoplasmic distribution, copper is also seen in 
the lysosomes of hepatocytes and then finally solely in lysosomes in patients with advanced disease.  








 In the literature, the typical patient with Wilson's disease will develop cirrhosis in the second 
decade of life due to copper's damaging effect on liver parenchyma.  However, histopathological 
features consistent with cirrhosis have been found in patients as young as 5 years of age and other 
changes such as fibrosis and inflammation were found in Wilson’s disease patients as young as 4 
months and 23 months respectively10.  Due to these findings and others, there is not any proven 
relationship between age at diagnosis and progression to cirrhosis.  There are however some 
individuals with primarily neurological manifestations of Wilson’s disease who may not progress to 
cirrhosis.  Their liver histology will however may still show some abnormality. 
 
 There have been no standardized categories for the hepatic pathological injury progression in 
Wilson’s disease because of its heterogeneity of presentation.  Previous reports have categorized the 
clinical and pathological features in patients with Wilson's disease into: fatty liver, acute hepatitis, 
resembling autoimmune hepatitis, cirrhosis: compensated or decompensated and acute liver failure4.  
These categories however are not rigid and overlap is inevitable 
 
Clinical Presentation and Parameters 
 
As previously mentioned before, the challenge of Wilson's disease lies in its heterogeneous 
clinical presentation.  It can present predominantly with derangement of liver function, particularly in 
children.  Patients may present as completely asymptomatic and have incidental findings of elevated 
transaminases, or can present with symptoms resembling acute viral hepatitis, fulminant liver failure 
and decompensated cirrhosis.  Jaundice and hemolytic anemia are also relatively common occurrences 
in patients with Wilson’s disease.  Clinical findings – which contribute to the ambiguity of its diagnosis 
- include elevated gamma-globulin levels and positive ANA and anti-SMA14.   





In the second or third decades of life, neuropsychiatric disease is a more common initial 
presentation than clinical hepatic disease.  75% of cases present with neurological manifestations and 
25% present with both hepatic and neurological presentations after the age of 2010.  These 
neuropsychiatric changes include behavioral abnormalities, psychosis and Parkinsonian features 
(micrographia, tremor, dysarthria and spasticity among others).  Less frequently, extrahepatic non-
specific features that include renal dysfunction (aminoaciduria), EKG abnormalities and osteoarthritis 
may be the initial presentation.  While neuropsychiatric features are common initial findings, as the 
disease progresses, the most common finding is predominantly hepatic, varying from fatty change, to 
hepatitis to cirrhosis2.  Hepatocellular carcinoma is fairly uncommon in Wilson’s Disease although few 
cases have been reported14. 
 
The disease is typically diagnosed in patients between the ages of 5 and 40 years old, however 
molecular studies have found ATPB7 mutations in 70 year old patients6.  Diagnosis of Wilson's disease 
has proven difficult despite published diagnostic criteria.  The diagnosis typically involves the presence 
of Kaiser Fleischer (KF) rings, a ceruloplasmin less than 20mg/dl and measurement of liver copper 
levels. Liver copper levels > 250 micrograms/g dry weight (normal range <35 micrograms/g dry 
weight) and urinary copper content (24 hr urinary copper levels > 40mcg /24h4) support the diagnosis 
of Wilson’s disease .   While dry liver copper levels are the gold standard, acquiring a tissue sample 
from a patient with liver disease carries with it significant risk (bleeding due to coagulopathy, infection 
etc), thus other more routine chemistries are used in initial investigation.  Twenty-four hour urinary 
copper has also proven beneficial in the diagnosis of Wilson’s, however; collection is difficult, 
particularly in newborns.  In addition, in patients who were not suitably educated prior to testing, tap 
water washing of the urine bottle may contaminate the sample9. 





While the criteria mentioned here have been considered sufficient for the diagnosis of Wilson’s 
disease, there have been numerous reports of patients with overlooked Wilson’s disease when they 
were used, particularly in children.  In a recent study of 57 children with a previously received 
diagnosis of Wilson’s disease, KF rings were found in 50% of patients older than 8 years old and in 
only 7% of patients younger than 8 years of age10.  Diagnosis in these vague cases was complemented 
with urinary copper excretion before and after penicillamine (a copper chelator) challenge, copper 
excretion increased sixteen fold after penicillamine challenge.  Liver copper content (the current gold 
standard) was also used to establish the diagnosis in the absence of more common criteria. 
 
Aminotransferase levels are typically abnormal but have not yet been found to correlate with 
severity of the disease.   In some studies,the combination of an AST to ALT ratio greater than 2.2 and a 
Alkaline phosphatase to Bilirubin ratio greater than 4 has been shown to be consistent with Wilson's 
disease in patients presenting with acute liver failure with a sensitivity that approaches 100%4. 
 
With the discovery of more ATP7B mutations in Wilson’s disease, and the rapid advancement 
of genetic testing, it is plausible to assume that molecular testing may play a larger role in challenging 
cases of Wilson’s disease. However, due to the rare nature of the disease, routine molecular testing may 
prove low yield and not cost effective.  Nevertheless, it is recommended that such studies only be used 
in cases in which the diagnosis is difficult even with both clinical and biochemical testing4.  It must be 
noted though that most patients with Wilson’s disease are compound heterozygotes, thus genetic 
testing may only prove beneficial in populations with a high incidence of certain mutations such as 
those populations in the Canary Islands or other such areas with high consanguinity.   
 






There are few studies detailing the correlation of histopathological features of Wilson's disease 
with symptomatology or outcome10,15.  In one study in children with Wilson's disease, symptomatic 
patients were more likely to have cirrhosis while asymptomatic patients were more likely to have 
histological findings consistent with steatosis.  Also, in the same study, there were no significant 
correlations between clinical outcome and histopathological features.  In another study in which serial 
liver biopsies of twelve patients with Wilson's disease were reviewed, it was found that hepatic copper 





Treatment of the disease is most beneficial when diagnosed early in life.  Medical therapy is 
targeted toward reducing the amount of copper accumulations.  This can be done with copper chelation 
(trientine, penicillamine) or zinc, which acts by both reducing the intestinal absorption of copper and 
inducing the formation of the endogenous copper chelator metalothein. In some cases the copper 
chelator is combined with zinc as a combined therapy presumably to utilize to methods of increased 
copper excretion and decreased copper absorption16.   
 
In a 2010 retrospective study of 288 Wilson’s disease patients in Germany, discontinuation of 
zinc monotherapy and combination therapy occurred with greater frequency than in the cohort on 
chelator therapy alone.  The authors of this study blamed this apparent discontinuation of the high rate 
of adverse events in the zinc cohort. These events included death and liver transplantation and 




concluded that chelating agents proved more successful at preventing hepatic deterioration than zinc.  It 
was recommended that zinc therapy be an alternative for asymptomatic or in patients with solely 
neurological manifestations of Wilson’s disease16. 
 
Side effects of standard therapy with penicillamine include bone marrow toxicity, elastosis 
cutis, nephrotoxicity and lupus like syndrome.  These severe side effects often lead to noncompliance 
in roughly a third of patients16.   
 
Antioxidants such as Vitamin E are sometimes used as adjunctive therapy; its efficacy in 
decreasing clinical symptoms however is unknown due to a lack of studies.  Patients are also advised 
on low copper diets and avoidance of well water.  In the event of acute liver failure however, liver 

















Statement of purpose, specific hypothesis and specific aims 
 
Given that the presentation of Wilson’s disease was so variable, it was hypothesized that there 
was a relationship between the pathologic features, the clinical presentation and markers of liver injury 
(Liver Copper content, 24hr urinary copper, Transaminases, Bilirubin). The objective of this study was 
to fully characterize the varying pathologic changes in the livers of patients with Wilson's disease and 






















Materials and Methods 
 
Pathology specimens from 14 patients with an established diagnosis of Wilson disease were 
retrieved from the hospital database. Patients were selected based on their fulfillment of either clinical, 
laboratory or genetic criteria for Wilson disease as well as the availability of surgical pathology 
material for review.  The demographics, clinical presentation, laboratory data, including alanine 
aminotransferase (ALT), aspartate aminotranserase (AST), alkaline phosphatase (ALK), prothrombin 
time (PT)/international normalized ratio (INR), total and direct bilirubin (TB/DB), alphafetoprotein 
(AFP), urine copper (Cu) and ceruloplasmin (CP), imaging, studies and clinical progression were 
reviewed.  Routine H&E, Trichrome, Rhodanine copper and Perl iron stains performed on liver 
biopsies and/or resections were reviewed and the histological features documented. Pathologic changes 
were staged using the Batts and Ludwig criteria17 (0:No fibrosis, 1: Fibrous portal expansion, 2: 
Periportal or Rare portal- portal septa, 3: Fibrous septa with architectural distortion; no obvious 
cirrhosis 4: Cirrhosis). Steatosis was characterized as mild (0-30%), moderate (>30% - 60%) and 

















   Pt # Clinical History 





1 54 y/o male presented 
with Parkinsonian 
symptoms with 











No significant fibrosis (Stage 0), minimal 
portal inflammation, no interface hepatitis, 
patchy balloon degeneration and some 
glycogenated nuclei. No significant 
steatosis. Copper and Iron negative 
2 37 y/o male evaluated 
for elevated 
transaminases 




Mild portal fibrosis, stage 1. Minimal 
portal inflammation, no interface hepatitis; 
Mild macrovesicular and moderate 
microvesicular steatosis.  Some 
glycogenated nuclei, patchy ground glass-
like hepatocytes. Copper and Iron 
negative. 
 
10 7 y/o male evaluated 







3   Biopsy Mild portal fibrosis,stage 1 minimal portal 
inflammation. Moderate macrovesicular 
and microvesicular steatosis with focal 
hepatocellular ballooning. Scattered 
glycogenated nuclei. No copper or iron 
11 18 y/o  male evaluated 
for persistently 
elevated transaminases 







Biopsy Mild portal fibrosis, stage 1 minimal portal 
inflammation, no significant interface 
hepatitis. Abundant glycogenated nuclei, 
patchy ballooning/degeneration, no 
significant steatosis, no Mallory. Negative 
iron and copper. 
7 35 y/o female with 
long standing 
Wilson’s disease 
   600 Biopsy Portal, periportal and pericentral fibrosis 
with focal bridging without cirrhosis 
(Stage 3). Also prominent sinusoidal 
fibrosis. Mild to moderate lymphocytic 
inflammation, mild interface hepatitis and 
mild bile ductular proliferation. Lobular 
disarray, with moderate micro and 
macrovesicular steatosis (Grade 2-3 on a 
scale of 0 to 4), patchy hepatocellular 
swelling and occasional acidophil bodies.  
No Mallory hyaline. Copper and Iron 
negative.  
 





45, 37: 1.2 4 54 690 Transplant 
Hepatectom
y 
Cirrhosis. Mild to moderate 
lymphoplasmacytic septal inflammation, 
mild ductular proliferation. No significant 
interface hepatitis. Granular eosinophilc 
cytoplasm with minimal steatosis (<1%). 
Rare Mallory, no glycogenated nuclei.  
Copper in rare periportal hepatocytes. Iron 
negative 
 
12 51 y/o male      Biopsy Portal, periportal and focal bridging 
fibrosis, stage 3. mild to moderate 
lymohocytic and neutrophilic portal 
inflammation with mild interface activity.  
Mild microvesicular steatosis with 
occasional ballooning degeneration and 
Mallory. No glycogenated nuclei. Iron 
negative, copper not done.  
3 14 y/o female 
presented with acu  




7   Transplant 
hepatectomy 
Cirrhosis. Moderate portal 
lymph pl smacyt c inflammation with 
moderate to arked i terface ductular 
activity; Moderate steatosis, Mallory 
hyaline, s attered neutrophilic and 
lymphocytic lobu ar inflammatio  with 
hydropically degenerat d hepat cytes with 
h p ocellular cholestasis and bile plugs.  
Occasional acidophilic bodies. Focal 
copper positivity in periseptal hep tocytes. 
Iron (1+) p sitive in occasional hepatocyte 
in macrophages 











Biopsy Bridging fibrosis, stage 3, mark d 
pericellul r fibrosis. Marked portal 
lymphoplasmacytic, eosininophillic and 
neutrophillic inflammation with rked 
terface inflammatory and ductul r 
activity. Lo lar disarray with xtensive 
b llooning degeneration, abunda t 
glycogenated nuclei and rare Mallory 
hyaline. Hypereosinophilc hepatocytes. 
Ir n and co per negative 
5 28 y/o male diagnosed 
by bi psy after sister 








C rrhosis, with abundant pericellular
fibrosis. Extensive parenchymal loss, with 
interface ductular activity and marked 
hep tocellular and cannali ular cholestasis. 
Extensive ballooning degeneration with 
moderate lymph plasmacytic 
inflammation and some glycog nated 
nuclei. Hypereosinophillic hepatocytes.  
Rare copper, Iron in hep tocytes (2+) 




47, 36: 1.3 3   Explant Cirrhosis with parenchymal dropout, 
marked septal lymphoplasmacytic and 
some eosinophilic inflammation with 
ductular prol feration. Mild interface 
hepatitis. No sign ficant nodu r 





Table 1.  Available demographic data and histopathology for all patients with Wilson’s disease. 
Table 2.  Available clinical/laboratory data.  NN/M (Near normal/Mild), CH/C (Chronic Hepatitis/Cirrhosis), AOCI (Acute 
on Chronic Injury) 




47, 36: 1.3 3   Explant Cirrhosis with parenchymal dropout, 
marked septal lymphoplasmacytic and 
some eosinophilic inflammation with 
ductular proliferation. Mild interface 
hepatitis. No significant nodular 
inflammation; giant cell change with 
periportal ballooning degeneration, 
cholestasis, early Mallory and occasional 
foam cell appearance. Iron in hepatocytes 
(3+) 
9 17y/o female 
presented with scleral 







 Explant Cirrhosis, mild chronic septal 
inflammation with moderate bile ductular 
proliferation. Mild to moderate 
macrovesicular steatosis, extensive 
ballooning degeneration with focally 
prominent Mallory hyaline. Marked 
Hepatocellular and canalicular cholestasis 
with focally marked copper accumulation, 
mild hepatocellular iron. 
 
 
13 64y/o female with 
long standing 
Wilson’s disease, 




17   Explant Cirrhosis. Abundant pericellular fibrosis. 
Mild lymphoplasmacytic septal 
inflammation, and ductular proliferation, 
conspicuous acidophil bodies, marked 
cholestasis.  Extensive ballooning 
degeneration, cholestasis and occasional 
periportal Mallory bodies. Copper stains 
are positive in occasional hepatocytes. 
Rare iron.   
14 13y/o male     Biopsy Cirrhosis. Abundant pericellular fibrosis. 
Mild lymphoplasmacytic septal 
inflammation, and ductular proliferation, 
conspicuous acidophil bodies, marked 
cholestasis.  Extensive ballooning 
degeneration, cholestasis and occasional 
periportal Mallory bodies. Copper stains 
are positive in occasional hepatocytes. 
Rare iron.   











Plts Hbg Alb 
(<1.2) (<0.2) 
ALK/TB 
1 18 19 0.9 59 10.9 1 440 14.3 4.3 0.34 0.1 173.5 
2 70 150 0.46 NA NA NA NA NA NA NA NA NA 
10 118 87 1.3 279 10.1 1 408 12.1 4.2 0.23 0.06 1213.0 
11 
NN/M 
77 239 0.3 122 10.5 0.9 168 15.7 4.7 1.71 0.32 71.3 
8 CH/C 45 37 1.2 135 14.9 1.5 71 13.3 3 1.38 0.34 97.8 
3 133 34 3.9 15 17.9 2.2 197 4.5 3.4 10.5 6.56 1.4 
4 27 44 0.6 163 13.6 1.2 75 14 4.7 0.93 0.18 175.3 
5 131 101 1.3 147 22 2.2 159 6.2 2.4 8.64 5.45 17.0 
6 47 36 1.3 99 21.9 3.6 67 10.1 3 8.16 3.98 12.1 
9 173 8 21.6 2 29.6 2.9 146 9.5 2.3 47.8 39.5 0.0 
13 
AOCI 
198 50 3.9 162 35.6 8.8 158 11.4 2 22.7 17 7.1 
AVG 94.2 73.2 3.6 118 18.7 2.5 189 11.1 3.4 10.2 7.4 11.6 
Sd 60.2 67 68.7 80.9 8.6 2.4 132 3.6 1 15 12.5 5.4 





Demographics, specimens, histopathology, clinical and laboratory data are presented in Tables 
1 and 2.  Cases highlighted in green correspond to the near normal/mild category; cases in blue 





Of the cases reviewed, there were 8 males and 6 females of age ranges 7 – 64 years at time of 
biopsy/resection, with a mean age of 31 +.18 years.  2 Patients were Caucasian, 2 were Asian, 1 was 




All but one patient was diagnosed based on an initial presentation of symptoms related to or 
with incidentally discovered deranged liver. Presentations ranged from acute liver failure to 
incidentally elevated transaminases in a virtually asymptomatic patient. The exception was a 54-year-
old man who presented primarily with neuropsychiatric symptoms, which included Parkinsonian 
features, significant anxiety and intermittent depression.  He had no abnormalities of liver enzymes, 
however, was found to have a low serum ceruloplasmin. Diagnosis of Wilson disease was confirmed 




Ceruloplasmin was available in 8 patients and ranged from 3-22U/L with a mean of 9+.7U/L.  




One patient had a normal ceruloplasmin at 22U/L, in this case the diagnosis was based on 
histopathology findings and a KF ring on exam.  AFP, which was also available in 8 patients, was 
elevated in 4 patients (range 3 to 40U/L, mean 16+.16U/L).  None of these patients however developed 
Hepatocellular Carcinoma. 
 
Eight of ten patients with available data had elevated AST levels (range 18 to 198U/L, mean 
97+.62U/L) while seven of ten patients had elevated ALT levels (range 8 to 239U/L, mean 
65+.67U/L).  The AST/ALT levels were > 2.2 in two patients who presented with acute liver failure.   
ALK levels were elevated in five patients (range 2 to 279U/L, mean 118+.80U/L).  TB values were 
elevated in seven of ten patients (range 0.34 to 47.8U/L, mean 10.2+.14.9U/L) while DB values were 
also elevated in seven patients (range 0.06 to 39.5U/L, mean 7.3+.12.5U/L).  ALK:TB ratio was less 
than 4 in only 2 patients (mean ratio 11.6+5.4).   
 
Dry Liver Copper values were available for seven patients.   Six of the seven values were well 
above the suggested 250mcg/g (mean 603 + 355mcg/g) cut off for Wilson’s disease.  There was one 
patient in the ‘Acute on Chronic Injury’ category with a liver copper value of 69 mcg/g.  There was no 
observed correlation between these values and the level of histopathological injury. 
 
Urinary Copper values were available for only six patients.  All values were well above the 
suggested 20mcg/24h (mean 2378+ 4878mcg/24h).  Values increased with increasing levels of hepatic 
injury (Table 1). 
 
Most patients presented with a coagulopathy, thrombocytopenia and anemia (mean INR 
2.5+.2.4U/L, platelets of 188+.132 x103/uL and Hemoglobin (Hb) of 11+.4U/L (Table 2).  







Right upper quadrant ultrasounds were reported on all patients.  The most commonly reported 
liver abnormalities were hepatomegaly, increased echogenicity, heterogeneity and nodularity consistent 
with cirrhosis.  The impression on imaging correlated with biopsy findings in all but one patient, in 




Patients were placed into three groups based on their pattern of histopathological liver injury 
and clinical correlate: Near normal/mild liver injury, chronic hepatitis (which included chronic hepatitis 
with or without cirrhosis), acute on chronic hepatitis and decompensated cirrhosis.  Near normal was 
defined as grade 0-1 fibrosis, chronic hepatitis18 as hepatocellular necroinflammatory lesions with 
parenchymal dropout, lymphocytic inflammation and greater than grade 1 fibrosis, cirrhosis as defined 
nodular fibrosis and acute on chronic injury was defined as lobular disarray or other acute changes on a 




Typical findings associated with Wilson disease were seen. These included glycogenated 
nuclei, steatosis and Mallory bodies.  Cases that were devoid of steatosis were cirrhotic (5 and 6) and 
the most marked steatosis was seen in samples with minimal fibrosis. Hepatocyte hypereosinophila of 
unclear significance was observed in two cases. 







 There were four patients in the "Near normal/mild” category.  While the fibrosis grades were 0-
1, the steatosis grades ranged from 0 – 3.  Biopsies in this category were significant for mild portal 
fibrosis in three of the four cases; architecture was preserved in all cases (Figure  1A).  There was an 
absence of interface hepatitis, lobular inflammation, Mallory hyaline, or copper accumulation by 
staining.  Glycogenated nuclei were seen in all cases (Figure 1B), as was patchy ballooning 
degeneration. All patients were male and ranged in age from 7 -54 years.  One patient presented with 
non-hepatic complaints while the others were noted to have asymptomatic persistent increases in 
transaminases, the most prominently elevated occurring in a patient with Stage 1 fibrosis.  Bilirubin 
was normal in all patients while ALK was elevated in three of the four patients.  One patient, an 18 
year old man, had a more marked elevation in ALT than AST, which is not typically seen in Wilson 
disease.  Hepatomegaly was the only ultrasonographic finding of significance in this group.   




Below are details of patients in this category 
 
Patient #1 was a 54 y/o male who presented with predominantly neuropsychiatric complaints; 
there was no steatosis in his biopsy.  However glycogenated nuclei and mild ballooning degeneration 
were observed.   
 
Patient #2 was a 37y/o male evaluated for elevated transaminases.  His biopsy was significant 
for moderate microvesicular steatosis and glycogenated nuclei.   
 
Patient #10 is a 7 year old male who presented with an initial diagnosis of Kawasaki's disease 
(strawberry tongue, fevers).  Upon further testing, abnormal liver enzymes were noted and the patient 




underwent work up for liver disease.  AST, ALT were elevated at presentation, Ceruloplasmin was low 
at 3.  Copper and iron stains were negative.  His biopsy was consistent with stage 3 steatosis, but grade 
1 fibrosis.  There were few glycogenated nuclei and minimal portal inflammation. 
 
 Patient #11 was an 18 year old male who presented asymptomatically with persistent elevations 
in transaminases.  His AST and ALT were elevated (notably, this patient had a much more elevated 
ALT than AST, not typically seen in Wilson's disease).  All other lab values were within normal limits.  
Histopathology of the biopsy specimen revealed negative copper and iron staining, grade 3 steatosis 
and grade 1 fibrosis.  Abundant glycogenated nuclei were seen as well as minimal portal inflammation 





 There were two patients with bridging fibrosis and one with cirrhosis in this group (Figure 2A). 
Sinusoidal fibrosis was also prominent in one of these cases. All three cases were devoid of significant 
acute changes with mild to moderate portal inflammation, none to mild interface inflammatory activity 
and only patchy ballooning degeneration and occasional acidophil bodies, (Figure 2.). Neither of the 
two cases with bridging fibrosis had copper or iron deposition and steatosis was mild to focally 
moderate. The cirrhotic patient had rare Mallory hyaline and copper in rare periportal hepatocytes 
(Figure 2B). Steatosis was minimal in this group.   
 
 Of the patients with bridging fibrosis, one patient was male, the other female. No laboratory 
data is available on either patient. The cirrhotic patient presented with features of decompensated 







Below are details of patients in this category 
 
 Patient #7 was a 35y/o female with long standing Wilson’s disease.  Biopsy report showed 
sinusoidal fibrosis (periportal and pericentral) with focal bridging but without cirrhosis.  Lobular 
disarray was noted. Fibrosis grade 3, Steatosis grade 2.  Mild to moderate chronic inflammation was 
noted with mild interface hepatitis and absent cholestasis or Mallory bodies.  Copper and iron stain was 
negative.  
 




 Patient #8 was a 50y/o female who was living with Wilson's since the age of 8 and on zinc 
therapy; she had an orthotopic liver transplant in 2008.  Her labs were notable for mild elevations in 
transaminases and bilirubin as well as low platelets on presentation.  Her biopsy was significant for 
well established macronodular cirrhosis and mild to moderate lymphoplasmacytic infiltrates as well as 
ductular proliferation.  There was however no significant steatosis or glycogenated nuclei in this 
patient. 
 
 Patient #12 was a 51y/o male with Wilson’s disease; there were no laboratory data available.  
However, his histopathology revealed portal, periportal and bridging fibrosis, mild to moderate 
lymphocytic and neutrophillic infiltrate.  No glycogenated nuclei were seen. Grade 1 steatosis and few 
Mallory bodies 
 
Acute on Chronic Injury 
 
This represented the major pattern seen in this review.  There were seven patients in the “Acute 
on Chronic Injury” category.  There were six cases with cirrhosis and one with bridging fibrosis.  
Typical markers of acute hepatic injury (i.e. parenchymal dropout, necroinflammatory activity,) were 
observed in all specimens (Figure 3. A-D).  More specifically, biopsies and liver explants were 
significant for lobular, portal and septal inflammation of varying degrees and lobular disarray was a 
consistent feature.  The inflammatory infiltrate was primarily lymphocytic although eosiniphillic and 
neutrophillic inflammation was seen in a minority of the specimens.  Moderate to marked periportal 
lymphoplasmacytic inflammation was observed in three of the specimens while mild to moderate 
chronic septal lymphoplasmacytic inflammation was observed in the other four cases.   Neutrophillic 
inflammation was seen in only two of the seven cases.  Mild to marked interface hepatitis and ductular 




activity was present in four of the seven cases.  Extensive ballooning degeneration, glycogenated nuclei 
and acidophil bodies were present in all of the cases while Mallory bodies and cholestasis were 
observed in six of the seven specimens.  Steatosis was seen in three of the seven cases, with grades of 
1- 2.  Copper staining was positive in five of the seven samples, staining ranged from diffusely positive 
to occasional hepatocyte staining (Figure 4A, B).  Iron staining was strongly positive (2+, 3+) in two 
cases (Figure 4C, D) 
 
In terms of clinical presentation, patients in this group ranged in age 13-64y/o, with a mean age 
of 25.   There were four females and three males.  All patients presented with fulminant, subfulminant 
hepatic failure or decompensated cirrhosis.  Other significant clinical findings in this group included 
coagulopathy and varying degrees of cytopenias.  Transaminases were available for six of the seven 
patients. AST levels were elevated in all but one patient.  ALT levels were also elevated in six of seven 
patients.  AST/ALT values were greater than 2.2 in 3 of 7 patients in this category. Ceruloplasmin was 
decreased in five of the six patients.  TB was elevated in all patients while DB was elevated in five of 
six of the patients.  ALK in this group ranged from 2-163U/L, three patients presented with elevated 
values. In previous studies, patients with Wilson’s disease presenting with fulminant hepatic failure 
typically have ALK/TB ratios far less than 44.  ALK/TB values were less than 4 in only two patients 
presenting in this category  (#3 and #9).  There were only two patients with available dry copper values 
in this category and one patient (#5) had a value below the suggested criteria for Wilson’s disease.  
Interestingly,  urine copper levels in this category were well above suggested criteria ranging from 
1559mcg/24h to 12,265mcg/24h.   Common ultrasonographic findings included shrunken 
heterogeneous hyperechoic livers consistent with cirrhosis.  
 
 










Below are details of patients in this category 
 
Patient #3 was a 14 year old female admitted in acute fulminant hepatic failure.  Pathology was 
notable for parenchymal loss, lymphaplasmacytic inflammation, moderate ductular proliferation and 
periseptal acidophil bodies.   In this case, Copper stains were variable but most prominent in periseptal 
hepatocytes.  In terms of other staining, iron was 1+ in macrophages and in periportal areas.  The 
steatosis grade was 1, with fibrosis grade 4.  AST levels were elevated in this patient, ALT levels 
remained normal.  Chemistries were also notable for hyperbilirubinemia and anemia. 
 
Patient #4 is a 23 year old male presenting with epigastric abdominal pain diagnosed as 




'subfulminant hepatic failure',  Liver enzymes were mildly elevated.  Glycogenated nuclei were present 
in his biopsy as was lymphoplasmacytic and eosinophillic portal inflammation and ballooning 
degeneration.  There was marked interface and ductular activity and particularly eosinophillic 
hepatocytes.  Copper and iron stains were negative.  Fibrosis grade was 3, however there was no 
steatosis. 
 
 Patient #5 was a 28 year old male with elevated transaminases and hyperbilirubinemia whose 
hepatectomy specimen was noticeable for glycogenated nuclei, extensive parenchymal loss and marked 
cholestasis.  The copper staining on this specimen was rare.  Iron stains were negative.  Fibrosis grade 
4, Steatosis grade zero.  There were also hypereosinophillic hepatocytes in this case along with 
intranodular lymphoplasmocytic inflammation.  This patient had a dry copper level of 69 mcg/g 
however his urine copper values were 1559mcg/g. 
 
Patient #6 was a 19 year old female who presented from Puerto Rico with rash and abnormal 
liver enzymes, further investigation revealed Wilson's.  Marked portal inflammation, 
lymphoplasmacytic inflammation, cholestasis and early Mallory bodies. Copper and Iron stains were 
positive (with Copper being localized to periportal areas) and seen more prominently within larger 
nodules. Steatosis and glycogenated nuclei was absent in this case.   Patient had very mildly elevated 
liver enzymes and hyperbilirubinemia.   
 
Patient #9 was a 17 year old presented with rash and epigastric pain with abnormal liver 
enzymes on presentation.   This patient had a normal ceruloplasmin (22mmol/L).  Her AST was 
elevated but her ALT was low normal.  Her alkaline phosphatase was also decreased at 2mmol/L.  She 
was also noted to have significant hyperbilirubinemia and mild coagulopathy.  Pathology was 




significant for grade 2 steatosis, grade 4 fibrosis (cirrhosis) and positive iron and copper staining.  
There were focally abundant Mallory hyaline.  Mild to moderate chronic inflammation with cholestasis 
and regenerative nodules were also noted. 
 
Patient #13 was a 64 year old female with long standing Wilson’s disease.  She had been treated 
with penicillamine and was switched to zinc because of poor tolerance of the former.  The patient 
eventually had an OLT in 2007 due to acute liver failure.  AST and ALT were elevated (AST/ALT>2). 
Notably in this patient’s labs were an increased total bilirubin with normal direct (perhaps due to 
hemolytic anemia seen in Wilson's patients).  Histopathology revealed grade 2 steatosis and grade 4 
fibrosis with iron and copper stains both being positive in occasional hepatocytes.  There was mild 
septal inflammation, marked cholestasis, glycogenated nuclei and some Mallory bodies. 
 
Patient #14 is a 13y/o male received as a consult whose biopsy was negative for both iron and 

















As demonstrated in this review, both the anatomic and clinical presentations of Wilson’s 
disease are heterogeneous.  Its course is also affected by timing and tolerance of treatment. As 
demonstrated in prior studies, the earlier the treatment, the better the outcome.  In this study, we aimed 
to first categorize these patients on the basis of histopathological injury of their biopsies and 
hepatectomies.  The pathology and clinical parameters were then detailed and attempts were made at 
correlation.  
 
Our review supports the pathology of the early stages of Wilson disease as represented by 
steatosis and glycogenated nuclei, often without accumulation of copper. The most consistent finding 
in this group of near normal liver biopsies is glycogenated nuclei.  The pathogenesis of these 
glycogenated nuclei is largely unknown, however, it has been described to be due to complex sugars 
that deposit in the nuclei of the hepatocyte.  Glycogenated nuclei have been seen in NASH (Non-
Alcoholic Steatohepatitis), Diabetes Mellitus and Wilson’s disease years before symptoms begin14.  It 
is however presumed that this fairly nonspecific finding may represent very early hepatic injury even 
though glycogenated nuclei have been observed in biopsies of healthy individuals14.    
 
Interestingly, with worsening of histopathological injury from near normal to definite chronic 
hepatitis to acute on chronic injury, the findings found in this review were not entirely consistent with 
those detailed before14.  This provides further evidence of the difficulty of the diagnosis of Wilson’s 
disease for the pathologist.  In the ‘Chronic Hepatitis NOS’ category, for example, lymphoplasmacytic 
inflammation has been suggested as a feature to distinguish Wilson’s disease hepatitis from hepatitides 
of other etiologies14 but is clearly not a specific enough change to utilize in this setting.  It is important 




to note however that the previously ubiquitous glycogenated nuclei found in early stages of the disease 
were notably absent in cases of chronic hepatitis and compensated cirrhosis.  In addition unlike 
previous reports, copper staining was rare if not absent in most of these cases.   
 
Oddly, as the disease appears to progress, either as decompensated cirrhosis or acute injury on 
chronic hepatitis, abundant glycogenated nuclei are seen.  Of note, in this category, there was also one 
case with giant cell change, a finding typically seen in autoimmune hepatitis. This patient however did 
not fulfill diagnostic criteria of autoimmune hepatitis.  
 
Another significant observation is the overlap between acute on chronic liver injury in Wilson’s 
disease and other features such as cholestasis and iron overload.  In particular, since ultrastructural 
features may overlap with those of other cholestatic disorders, ultrastractural analysis may have limited 
application in patients with acute liver injury and cholestasis.   
 
 
Diagnosis: Anatomic and Clinical pathology correlations 
 
Early diagnosis of Wilson's disease is necessary, as treatment with copper chelators has been 
proven to delay the subsequent hepatic and lenticular degeneration cause by copper buildup.  Thus 
thorough characterization of patients presenting in this review's “Near Normal/Mild” category is 
essential.  As seen above, cases in this category were significant for mild elevations in transaminases 
on clinical presentation and steatosis and glycogenated nuclei on biopsy.  Presented as such, this 
perhaps generates the largest differential for the pathologist without any further molecular or genetic 
studies given that in all four cases iron and copper staining were negative.  The differential may include 




any of the far more common causes of mild chronic hepatitis (autoimmune, viral, toxin).  Regarding 
trends of clinical parameters in this group, there were varying elevations in transaminases (mostly 
AST>ALT as seen in previous reports of Wilson's disease).  Importantly, transaminases were not as 
high as the levels seen in the viral hepatitides (AST and ALT levels are often 5 – 10 times the upper 
level of normal) nor were AST/ALT ratios greater than two as typically seen in alcoholic hepatitis.  
Dry copper levels were also elevated.  However, Total and Direct Bilirubin were normal in all cases but 
one.  Here, as mentioned in previous studies, copper quantization proves to be the only definite clinical 
lab value in diagnosing liver disease. It is therefore imperative that when this minimal degree of liver 
changes are noted, if a suspicion exists for Wilson disease based on other parameters, liver quantization 
is performed.  
 
In the subsequent groups representing patients with increasing hepatic injury due to Wilson’s 
disease, clinical parameters (transaminases) increased with hepatic injury but were not consistent with 
previous reports.  AST/ALT ratios in the acute on chronic category were greater than 2.2 in only two 
patients, the same number had ALK/TB ratios less than 4.  This is unlike previous studies which have 
shown that the combination of AST/ALT > 2.2 and ALK/TB > 4 is consistent with Wilson’s disease in 
patients presenting with acute liver failure.  This is a retrospective study and it is important to note that 
some of the patients at Yale New Haven Hospital were already on treatment at the time of their 
presentation, this may have skewed the results.  Also, such differences in transaminase and bilirubin 
levels illustrate the unreliability of solely clinical parameters in diagnosing Wilson’s disease. 
 
While dry copper levels did not increase with increasing levels of hepatic injury, urine copper 
levels – in those patients with available data – did.  This finding may prove important in diagnosing 
and following patients with Wilson’s disease.  Dry copper levels have been the gold standard of 




diagnosis but this study shows a patient with Wilson’s disease with a dry copper level of 69mcg/g, well 
under the suggested criteria of 250mcg/g.  His urine however surpassed the cut-off and diagnosis was 
confirmed.  Apart from illustrating the difficulty of diagnosis, this finding shows urine copper to 
perhaps be more reliable in assessing not only the presence but the severity of Wilson’s disease.  There 
are however difficulties with collection of 24h urine samples and many opportunities for 
contamination. 
 
This study replicates the often-repeated observation that a negative liver copper stain does not 
exclude Wilson disease.  Previous investigation into Timm's silver stain (not used in this study) found 
it to be sensitive to the cytosolic distribution of copper in the early stages of Wilson's disease.  The 
standard rhodanine and rubeanic stains are often negative at these stages19.   In a study to assess the 
sensitivity of the three most commonly used stains (Timm's, rhodanine and orcein), 79 liver biopsies 
from patients with Wilson's disease were categorized into three different groups: steatosis, interface 
hepatitis and chronic hepatitis/cirrhosis.  Timm's s silver stain was found to be more sensitive in its 
detection of copper in all three groups.  This study also demonstrated the unreliability of histochemical 
detection of copper in Wilson's disease.  Timm's silver stain, for example, only stained 58.6% of 
biopsies with chronic hepatitis/cirrhosis, 40.1% of biopsies with interface hepatitis and 30.4% with 
steatosis.  It has been suggested that Timm's be used in referred cases with limited tissue available for 
staining19.   
 
In addition to emphasizing the fallibility of the copper stain, this study shows the absence of 
any correlation between copper staining and dry copper levels.  In fact, positive copper and iron stains 
seemed to correlate more with increasing tissue injury than actual copper levels.  Patient #5 – in the 
acute on chronic injury category - for example had a dry copper level of 69mcg/g and a positive copper 




stain, while Patient #1 – in the near normal/mild category – had a dry copper level of 650mcg/g with a 
negative copper stain.  This difference may be because rhodanine is less likely to stain the abundant 
cytoplasmic copper present in early stages of the disease and may be more apt to stain lysosomal 
copper present in advanced stages of the disease. 
 
Interestingly also, only a minority of patients have bland chronic hepatitis, with or without 
cirrhosis. The vast majority of cases reported here show some degree of acute liver injury, exemplified 
by any combination of ballooning degeneration, apoptosis, parenchymal dropout with lobular collapse. 
In addition, as has been observed, in these cases with acute injury, cholestasis is a prominent feature, as 
is some measure of disordered iron metabolism and increased iron.   
 
The iron overload noted in the specimens in the acute on chronic liver injury category can be 
due to the intravascular hemolysis seen in some reported cases of Wilson’s disease, unfortunately there 
were no serum iron levels to correlate with the histopathological findings.  The suggested cause of this 
hemolytic anemia is the increased oxidative stress caused by copper accumulation within the cells20.  
 
The iron overload could also be due to the hypoceruloplasminemia (and potentially, the 
hypocupremia) in these patients.  As mentioned before though not completely characterized, 
ceruloplasmin is a ferroxidase essential for iron mobilization and transport thus it can be assumed that 
the decreased ceruloplasmin seen in Wilson’s disease patients would lead to a build up of iron in major 
organs of the body and an absence thereof in the serum.  Aceruloplasminemia, an autosomal recessive 
disease caused by loss of function mutations in the ceruloplasmin gene, illustrates the effect of low to 
absent ceruloplasmin on iron metabolism.  In this case, iron mobilization is severely impaired and 
builds up in the pancreas, liver and brain.   Hypoceruloplasminemia does not wholly explain iron 




overload however as iron staining was positive in one of the reviewed cases, this patient had a 
ceruloplasmin of 22U/L.  It is important to note though that ceruloplasmin is an acute phase reactant, 
thus high levels are to be expected in patients with acute on chronic injury. 
 
Nevertheless, iron proves to be an important marker of liver injury in the context of Wilson's 
disease as copper has been previously found to play a crucial role in its metabolism not only in the 
context of ceruloplasmin but also in Cu dependent ATPases.  The ATP7A/ATP7B homologue found in 
Saccharomyces cervisae yeast Ccc2p has been characterized in previous studies as a copper dependent 
ATPase necessary for iron uptake21.  In future studies, in addition to the clinical parameters detailed 
above, it may be worthwhile to correlate dry iron levels with disease states in order to further detail 
diagnostic criteria, and to determine whether liver iron levels may be a useful marker of acute liver 
injury in the setting of Wilson disease.  
 
Because of the relative recent incorporation of molecular diagnostics into clinical practice and 
the rare nature of Wilson's disease, it is important to note that although Wilson's disease is 
characterized by a mutation in ATP7B, other mutations in other copper dependent ATPases or copper 
dependent proteins may be implicated in this disease of copper accumulation.  These varying mutations 
may potentially account for both the varied clinical presentations and varied patterns of 
histopathological injury seen above.  
 
Previous reports4 have categorized the clinical and pathological features in patients with Wilson 
disease into: fatty liver, acute hepatitis, resembling autoimmune hepatitis, cirrhosis: compensated or 
decompensated and acute liver failure. In this series, none of these patients with acute liver failure was 
without cirrhosis thus it may be possible that in some settings, such acute liver failure occurs only in 




the present of extensive prolonged liver damage. 
 
In this review, a clinical presentation of acute liver injury correlates with the histological 
features though not entirely consistent with previous reports. Correlation between other histological 
features and clinical parameters is less clear, though some trends were noted.  As seen in this study, 
despite varying levels, the ceruloplasmin remained low, if not low normal in most cases. Though 
copper staining has proved an unreliable method for initial diagnosis, the most severe cases with acute 
injury were more likely to stain positively with copper and therefore, unlike ceruloplasmin, may 
possibly correlate with severity of acute injury.   In addition, and perhaps most important, urine copper 
appears to correlate closely with hepatic injury and was positive in a case of Wilson’s disease in which 
dry liver copper was negative (according to diagnostic criteria).  Thus, this may prove beneficial in 
diagnosing and trending of disease although further studies are warranted.  Testing urinary copper also 
employs a far less invasive (and presumably safer) method of testing.  Both patient and physician 
should be thoroughly educated on 24h urine collection (avoidance of tap water and Foley catheters, 
usage of pediatric urine bags that do not contain copper) so as to minimize contamination.  
 
The characterization of Wilson disease still remains a challenge and while advances in 
molecular techniques may theoretically be able to facilitate diagnosis, these may prove prohibitively 
expensive given the increasing number of ATP7B mutations and the lack of prevalence of the disease.  
A thorough awareness of clinical presentation, varying histopathological features and clinical 
parameters that provide hints to both disease process and severity is therefore be useful in the clinical 
management and diagnosis of Wilson’s disease. 
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